🇯🇵June 11, 2026·Jun 11Industry

ベレキシブル®錠、悪性リンパ腫の中枢神経系への浸潤（既存治療が効果不十分または不適当な場合に限る）に対する効能または効果の追加に係る国内製造販売承認申請 | ONO CORPORATE

Publisher

Ono Pharmaceutical

Japan

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Ono Pharmaceutical
Region: Japan
Scope: Industry
Published: June 11, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on ono-pharma.com

Leave the platform to read the original full article on the publisher site.

Source: Ono Pharmaceutical

Scope: Industry

Open original article

Related coverage

More related coverage

Bristol-Myers Squibb News/5h ago

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Merck & Co. (MSD) News/6h ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Ipsen RSS/8h ago

Advancing Care in Renal Cell Carcinoma: Earlier Treatment, Better Outcomes, and Stronger Support for Patients

Roche Newsroom/11h ago

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma